信達生物(01801.HK)與LG化學達成戰略合作協定 引進痛風領域全新黃嘌呤氧化酶抑制劑Tigulixostat
格隆匯12月15日丨信達生物(01801.HK)發佈公吿,集團與LG化學旗下的LG化學生命科學,就LG化學研發的臨牀後期創新藥物Tigulixostat(LG研發代號: LC350189,集團研發代號:IBI-350),一款治療痛風患者高尿酸血癥的全新非嘌呤類似物黃嘌呤氧化酶抑制劑(“XOI”),達成戰略合作和授權合約。
根據協定條款,集團將獲得Tigulixostat在中國的獨家開發和商業化權利。LG化學將獲得1000萬美金的合作首付款,並將有資格獲得總額不超過8550萬美金的潛在里程碑付款,以及基於中國地區年度淨銷售額的特許使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.